---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-000016"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2022-01-03T23:59:59+00:00"
generated_at: "2026-06-27T21:24:45.491236+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ovid licenses KCC2 activator library from AstraZeneca; $5M cash + $7.5M stock upfront

## Summary
- Exclusive worldwide license for early-stage small molecules targeting KCC2, including lead OV350.
- Upfront consideration: $5M cash + $7.5M in Ovid common stock (2,272,727 shares).
- Milestones up to $8M clinical, $45M regulatory, $150M commercial; royalties single-digit to 10%.
- AstraZeneca retains right of first negotiation at proof of clinical efficacy for strategic collaboration.
- OV350 shows in-vitro/in-vivo proof of concept in resistant epilepsy; Ovid to collaborate with Drs. Moss, Maguire.

## SEC filing metadata
- accession: 0001564590-22-000016
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2022-01-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000156459022000016/0001564590-22-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000156459022000016/ovid-8k_20211230.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-000016
- JSON: https://secwatch.observer/filing/0001564590-22-000016.json
- Plain text: https://secwatch.observer/filing/0001564590-22-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.